Market Place
Sourcing Support
All News #Library
Biotech
SK Bioscience, IDT, Vaxxas Picked for EU Flu Vaccine Program
26 Feb 2026 //
PR NEWSWIRE
Vaxxas Names Ex-Merck Global Vaccines Head David Peacock CEO
07 Jan 2026 //
GLOBENEWSWIRE
Vaxxas Secures TGA Licence To Manufacture Therapeutic Goods
14 Dec 2025 //
GLOBENEWSWIRE
Vaxxas Appoints Veteran Vaccine Leader to Board
10 Nov 2025 //
GLOBENEWSWIRE
ObvioHealth, Vaxxas Partner on Needle-Free Vaccine Tech Trials
28 Oct 2025 //
PR NEWSWIRE
Vaxxas Secures A$90M To Advance Needle-Free Vaccine Tech
25 Aug 2025 //
GLOBENEWSWIRE
Vaxxas Secures US Patent For Needle-Free Vaccines
18 Mar 2025 //
BUSINESSWIRE
Vaxxas Completes Enrollment In Largest HD-MAP Vaccine Trial
18 Feb 2025 //
BUSINESSWIRE
Vaxxas Appoints Global Vaccine Experts, Advances Needle-Free Tech
05 Feb 2025 //
BUSINESSWIRE
Vaxxas & CEPI Advance $4.8M For Needle-Free mRNA Vaccines
22 Jan 2025 //
BUSINESSWIRE
Vaxxas Wins BARDA Prize for Advancing Microarray Vaccines
13 Jan 2025 //
BUSINESSWIRE
Vaxxas Licenses Next-Gen RSV Vaccine from NIH
28 Oct 2024 //
BUSINESSWIRE
Vaxxas Starts Phase I Trial Of H7N9 Vaccine Using HD-MAP Technology
11 Sep 2024 //
BUSINESSWIRE
Vaxxas Announces and Publishes Successful Phase I Clinical Trial for Measles
26 Nov 2023 //
BUSINESSWIRE
Australia-Korea joint devp agreement for needle-free of typhoid vaccine
29 Aug 2023 //
BIOSPECTRUM ASIA
Vaxxas Awarded US$3.67 million from global charitable foundation
23 Aug 2023 //
BUSINESSWIRE
Vaxxas opens manufacturing facility for needle-free vaccine patch
19 Jun 2023 //
PHARMAFILE
Vaxxas Opens World-Class MFG Facility To Produce Needle-Free Vaccine Patch
17 Jun 2023 //
BUSINESSWIRE
Vaxxas Announces Results from PI Study of First Needle-Free COVID-19 Vaccine
05 Jun 2023 //
BUSINESSWIRE
Vaxxas Initiates Phase I Study of First Needle-Free IIV4 Delivered Using HD-MAP
10 Feb 2023 //
BUSINESSWIRE
Copyright © 2026 LePro PharmaCompass OPC Private Limited, All rights reserved.